Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine Pathology
Published in: Endocrine Pathology 1/2024

Open Access 16-02-2024 | Parathyroid Cancer | Images in Endocrine Pathology

Not All Parafibromin Deficiency Relates to Parathyroid Carcinoma: The Role of Morphological Assessment

Author: C. Christofer Juhlin

Published in: Endocrine Pathology | Issue 1/2024

Login to get access

Excerpt

A male in his early thirties, without any prior medical history, presented with a history of fatigue. Upon examination, mild hypercalcemia and elevated levels of parathyroid hormone (PTH) were observed. The patient was subsequently referred to our endocrine surgery department. Ultrasound and sestamibi scintigraphy revealed an enlarged right superior parathyroid gland measuring 20 mm. The patient had no family history suggestive of parathyroid disease or MEN1-related manifestations. A focused parathyroidectomy was performed. …
Literature
1.
Gill AJ, Lim G, Cheung VKY, Andrici J, Perry-Keene JL, Paik J, Sioson L, Clarkson A, Sheen A, Luxford C, Elston MS, Meyer-Rochow GY, Nano MT, Kruijff S, Engelsman AF, Sywak M, Sidhu SB, Delbridge LW, Robinson BG, Marsh DJ, Toon CW, Chou A, Clifton-Bligh RJ (2018) Parafibromin-deficient (HPT-JT Type, CDC73 mutated) parathyroid tumors demonstrate distinctive morphologic features. Am J Surg Pathol. https://​doi.​org/​10.​1097/​PAS.​0000000000001017​CrossRefPubMedPubMedCentral
2.
3.
4.
5.
Metadata
Title
Not All Parafibromin Deficiency Relates to Parathyroid Carcinoma: The Role of Morphological Assessment
Author
C. Christofer Juhlin
Publication date
16-02-2024
Publisher
Springer US
Published in
Endocrine Pathology / Issue 1/2024
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-024-09804-5

Other articles of this Issue 1/2024

Endocrine Pathology 1/2024 Go to the issue

Research

Clinical and Molecular Characteristics of Gonadotroph Pituitary Tumors According to the WHO Classification

Research

The Role of 5-Hydroxymethylcytosine as a Potential Epigenetic Biomarker in a Large Series of Thyroid Neoplasms

Correspondence

Focal Tall Cell Change in Papillary Thyroid Carcinoma: Lessons Learned from Practices Adopting Rigid Criteria (Height to Width Ratio of 3)

Research

Hand2 Immunohistochemistry in the Diagnosis of Paragangliomas and Other Neuroendocrine Neoplasms

Research

Artificial Intelligence Detected the Relationship Between Nuclear Morphological Features and Molecular Abnormalities of Papillary Thyroid Carcinoma

Images in Endocrine Pathology

Thyroid gland blastomycosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits